評論
打印
A New Migraine drug has been Approved, New hope for headache sufferers
偏頭痛新藥獲批 頭痛患者有了新希望
APPROXIMATELY 1 BILLION people across the globe sufer from migraines,
全球大約有10億人患有偏頭痛，
making the condition the world’s third most common illness,
這種疾病也因此成了世界上第三大常見疾病，
according to the Migraine Research Foundation.
偏頭痛研究基金會調查顯示。
Not only that, many sufferers—a disproportionate number of whom are women—
不僅如此，許多患者——患者大多為女性——
face doubt from doctors and peers who may downplay the pain.
還要面對可能低估他們的疼痛程度的醫生和同齡人的懷疑。
And yet the U.S. market has offered no drug expressly designed to prevent these debilitating headaches.
盡管如此，美國市場還是沒有專門用來預防這些令人難以承受的頭痛的藥物。
That changed on May 17, when the Food and Drug Administration approved Aimovig, a drug from Amgen and Novartis.
好在5月17日，情況有了好轉，因為這天，美國食品和藥物管理局批準了安進和諾華兩家公司合作研發的Aimovig。
Users take a monthly shot that targets a molecule thought to play a role in migraines
這一藥物專門作用于一種被認為與偏頭痛有關的分子，使用者每月只需注射一劑，
and has been shown in clinical trials to measurably reduce headache frequency for chronic sufferers.
臨床試驗證明，該種藥物顯著降低了慢性偏頭痛患者的頭痛頻率。
When the drug becomes widely available—which is scheduled to happen very soon—
這種藥物大量投入市場——這一天很快就會到來——以后，
more sufferers will be able to put it to the test,
就能有更多的患者來檢驗它的藥效了，
but it has already become invaluable to some patients in those trials.
但它對參與臨床試驗的那些患者而言，療效已經極其顯著了。
Susan Giordano, 58, who was plagued by up to 12 migraines a month, now hasn’t had one in a year.
58歲的蘇珊·佐丹奴原來偏頭痛的頻率高達一個月12次，現在已經有一年沒有復發了。
“The drug has really been lifetransforming,” Giordano says.
“這種藥物確實改變了我的生活，”佐丹奴說。
“which I don’t say lightly.”
“這種話我是不會輕易說的。”
譯文由可可原創，僅供學習交流使用，未經許可請勿轉載。
